FDA‐approved GAA inhibitors, such as acarbose or miglitol, are effective at improving insulin action and glycemic control while also being effective at reducing fatty liver in individuals with obesity and type 2 diabetes (Goda et al., 2007; Joubert et al., 1990; Komatsu et al., 2018; Nozaki et al., 2009). Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.